Efficacy and safety evaluation of pentoxifylline associated with other antioxidants in medical treatment of Peyronie's disease: a case-control study
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Peyronie's disease (PD) is a chronic disorder involving the tunica albuginea surrounding the corpora cavernosa of the penis. A conservative treatment is indicated in the first stage of disease. The aim of this study was to assess the therapeutic impact and possible side effects of treatment with pentoxifylline (PTX) in combination with other antioxidants in 307 patients with early-stage PD. Patients were subdivided into three groups: A, B, and C. Both groups, A and B, comprising of 206 patients, underwent treatment, whereas Group C was the control group (n=101). Treatment lasted 6 months and included the following: Group A: PTX 400 mg twice a day + propolis 600 mg/d + blueberry 160 mg/d + vitamin E 600 mg/d + diclofenac 4% gel twice/a day + PTX 100 mg via perilesional penile injection/every other week (12 injections in all); Group B: the same treatment as Group A except for the penile PTX injections. After the 6-month treatment course, we obtained the following results: actual mean decrease in plaque volume -46.9% and -24.8% in Group A and B, respectively (P<0.0001); mean curvature reduction -10.1° and -4.8°, respectively (P,0.0001); resolution of pain in 67.6% and 67.2% of cases, respectively (P=0.961); recovery of normal penile rigidity in 56.09% and 23.5% of cases, respectively (P=0.005). After 6 months, progression of disease was observed in all patients belonging to Group C: plaque volume +123.3%; curvature +15.7°; no recovery of penile rigidity. The statistically significant results of our study show that multimodal treatment with PTX in association with other antioxidants and topical diclofenac is efficacious in treating early-stage PD. Furthermore, treatment proved to be more effective when PTX was administered both orally and by penile injection. No serious adverse effects occurred.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gelbard, M., Goldstein, I., Hellstrom, W. J. G., McMahon, C. G., Smith, T., Tursi, J., Jones, N., Kaufman, G. J., & Carson, C. C. (2013) · Journal of Urology · doi:10.1016/j.juro.2013.01.087 · Cited by 466 · cited 1×
“Comparison with the results of other treatment plans that call for intraplaque penile injections (interferon, verapamil, and collagenase) further persuades us of the efficacy of multimodal therapy, especially when PTX is used, not only because of the brilliant results achieved in the main endpoints, but also especiall…”
ResultProposal: Trauma as the Cause of the Peyronie's Lesion
Devine, C. J. J., Somers, K. D., Jordan, G. H., & Schlossberg, S. M. (1997) · Journal of Urology · doi:10.1016/s0022-5347(01)65361-8 · Cited by 381
El-Sakka, A. I., Hassoba, H. M., Pillarisetty, R. J., Dahiya, R., & Lue, T. F. (1997) · Journal of Urology · doi:10.1016/s0022-5347(01)64223-x · Cited by 250
Gonzalez-Cadavid, N. F. (2009) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2008.01195.x · Cited by 172
Autophotography in evaluation of functional penile disorders
Kelâmi, A. (1983) · Urology · doi:10.1016/0090-4295(83)90210-8 · Cited by 89
Gene expression in Peyronie's disease
Gonzalez-Cadavid, N. F., Magee, T. R., Ferrini, M., Qian, A., Vernet, D., & Rajfer, J. (2002) · International Journal of Impotence Research · doi:10.1038/sj.ijir.3900873 · Cited by 84
Peyronie's disease in men under age 40: characteristics and outcome
Tefekli, A., Kandirali, E., Erol, H., Alp, T., Köksal, T., & Kadıoğlu, A. (2001) · International Journal of Impotence Research · doi:10.1038/sj.ijir.3900635 · Cited by 81
Role of oxidative stress and antioxidants in Peyronie’s disease
Sikka, S. C., & Hellstrom, W. J. G. (2002) · International Journal of Impotence Research · doi:10.1038/sj.ijir.3900880 · Cited by 77 · cited 2×
“Our research confirms that in this disease long-term treatment yields the best results; in consideration of the fact that the first stage of PD has a duration of approximately 6–18 months, short-term therapies should thus certainly be avoided.(23,26,79,80) Once again, multimodal therapy has been proven to be the best…”
BackgroundResultPaulis, G., & Brancato, T. (2012) · Inflammation & Allergy - Drug Targets · doi:10.2174/187152812798889321 · Cited by 60 · cited 1×
“kappa-light-chain-enhancer of activated B-cells, which in turn causes further gene expression of proinflammatory cytokines, as well as gene expression of collagen, fibrin, and inducible nitric oxide synthase.(18,23) The gradual local overproduction of collagen, associated with degradation–destruction of the elastic fi…”
BackgroundSelf-citationWNT2 Locus is Involved in Genetic Susceptibility of Peyronie’s Disease
Dolmans, G. H., Werker, P. M., de Jong, I. J., Nijman, R. J., Study, L. C., Wijmenga, C., & Ophoff, R. A. (2012) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2012.02704.x · Cited by 46
Significant alterations of serum cytokine levels in patients with Peyronie's disease
Zimmermann, R. P., Feil, G., Bock, C., Hoeltl, L., & Stenzl, A. (2008) · International braz j urol · doi:10.1590/s1677-55382008000400008 · Cited by 23
Cited by
Paulis, G., Romano, G., Paulis, L., & Barletta, D. (2017) · Advances in Urology · doi:10.1155/2017/4653512 · Cited by 44
Self-citationPaulis, G., De Giorgio, G., & Paulis, L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232415969 · Cited by 21
Self-citationConservative Therapy for Peyronie’s Disease: a Contemporary Review of the Literature
Yousif, A., Natale, C., & Hellstrom, W. J. G. (2021) · Current Urology Reports · doi:10.1007/s11934-020-01024-8 · Cited by 12
Clinical Presentation of Peyronie’s Disease: A Retrospective Study of 564 Cases
Paulis, G., De Giorgio, G., & Paulis, A. (2024) · Diagnostics · doi:10.3390/diagnostics14111125 · Cited by 11
Self-citation
Metadata
- Authors
- Paulis, G., Barletta, D., Turchi, P., Vitarelli, A., Dachille, G., Fabiani, A., & Romano, G.
- Venue
- Research and Reports in Urology
- Publisher
- Informa UK Limited
- Published
- 2015-12
- Volume
- 8
- Pages
- 1
- ISSN
- 1179-1551 (ISSN-L)
- 2253-2447
- OpenAlex
- W2228838626
- Cited by
- 37
- References
- 11
- FWCI
- 1.94
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.